Phenotypic Determinants of Vestibular Schwannomas
前庭神经鞘瘤的表型决定因素
基本信息
- 批准号:7390719
- 负责人:
- 金额:$ 30.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-05-10 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcoustic NeuromaAdolescenceAffectAge of OnsetAllelesAnalysis of VarianceAppearanceAstrocytomaBase PairingBilateralBiologicalBiological AssayBiometryBlindedBloodBlood CellsBrain StemCategoriesCellular MorphologyCerebellopontine Angle NeoplasmClassificationClinicalCluster AnalysisCodeConsultCranial NervesCystic NeoplasmDNADNA SequenceDNA-Protein InteractionDataData AnalysesDepositionDevelopmentDiagnosisDiseaseDoctor of MedicineDoctor of PhilosophyElectrophoretic Mobility Shift AssayElementsEndoglinEndoribonucleasesEpendymomaEpigenetic ProcessEpitopesEquilibriumExcisionExhibitsExonsFacial nerve structureFacial paralysisFrameshift MutationFreezingFutureGene ChipsGene ExpressionGene Expression ProfileGene MutationGenesGenetic PolymorphismGenetic TranscriptionGenomicsGenotypeGliomaGrowthHearingHemosiderinHistologicHumanHyperplasiaImmunohistochemistryIndividualInstitutesInternetKnockout MiceLaboratoriesLettersLifeLocalizedLocationLoss of HeterozygosityMagnetic Resonance ImagingMeasuresMethodsMethylationMicroarray AnalysisMicroinjectionsMissense MutationModificationMolecular ProfilingMorbidity - disease rateMosaicismMusMutationMutation AnalysisMyelin Basic ProteinsNatural HistoryNeurilemmomaNeuro-Oncological Ventral Antigen 2NeurofibromatosesNeurofibromatosis 2Neurofibromin 2Northern BlottingNucleic Acid Regulatory SequencesNumbersOhioOnset of illnessOther FindingOutcome StudyPancreatic ribonucleaseParaffin EmbeddingParesthesiaPartner in relationshipPathway interactionsPatientsPatternPharmacologic SubstancePhenotypePlayPolymerase Chain ReactionPrincipal InvestigatorPromoter RegionsProtein IsoformsProteinsRNARNA SplicingRadiationRateRegulationReporterReportingResearchResearch PersonnelReverse TranscriptionRibonucleasesRoleSamplingSchwann CellsScreening procedureSeveritiesSeverity of illnessSignal PathwaySignal TransductionSignaling ProteinSiteSolidSourceSpecimenSpinal NeoplasmsSplice-Site MutationStaining methodStainsStandards of Weights and MeasuresStatistical Data InterpretationSystemTestingTherapeuticThinkingTimeTissue SampleTissue-Specific Gene ExpressionTissuesTranscriptional ActivationTranscriptional RegulationTransgenesTransgenic MiceTransgenic OrganismsTreatment ProtocolsTreatment outcomeTrigeminal SystemTumor BiologyTumor Suppressor GenesTumor TissueUniversitiesUp-RegulationVariantbasecDNA Arraysdesignexpression vectorhearing impairmentinterestmalemedical schoolsmeningiomaprogramspromoterprotein expressionrapid growthresearch studytumortumorigenesisuptakevestibular pathway
项目摘要
DESCRIPTION (provided by applicant): Vestibular schwannomas in humans can cause morbidity associated with hearing and balance loss, facial paralysis and paresthesias, and occasionally life-threatening brainstem compression. Vestibular schwannomas can be divided into three general categories - unilateral spontaneous, neurofibromatosis type 2 (NF2) associated, and cystic-type vestibular schwannomas. Although quite distinct clinically, the source of phenotypic variation among schwannoma tumor types is currently unknown, but of great clinical interest. Furthermore, the optimal treatment regimens are not known because of a lack of understanding of fundamental tumor biology. Of the three types of tumors, NF2-associated vestibular schwannomas are the subject of the current proposal. The hallmark of NF2-associated vestibular schwannomas is bilateral tumor presentation. NF2 is historically subclassified into an aggressive and a mild form. Vestibular schwannomas are known to harbor mutations in the neurofibromatosis 2 (NF2) tumor suppressor gene; however, not every tumor carries a mutation in the NF2-coding region. A possible role for mutation or methylation in the NF2 regulatory regions has been suggested. The long-term objective of this study is to further identify and understand factors which affect the phenotypic expression of vestibular schwannomas. The principal hypotheses of this study to be tested are that 1) transcriptional regulation plays a role in vestibular schwannoma tumorigenesis and 2) phenotypic expression is altered by specific growth signaling pathways that are deregulated in vestibular schwannomas. In support of these hypotheses, four sets of experiments are proposed. In Specific Aim 1, they will examine the role of the regulatory region of the NF2 gene in schwannomas when mutations have not been identified in the coding region. Specific Aim 2 will examine in transgenic mice whether RhoB is an important downstream signaling target of the NF2 protein in Schwann cells. In the third Specific Aim, they will conduct a similar transgenic analysis to over-express endoglin in Schwann cells. This will be accomplished by mating the RhoB/endoglin transgenic mice with the conditional 7Vjr2-knockout mice to determine if there is any enhancement of the phenotype. In Specific Aim 4, they will continue to evaluate differentially expressed genes, which may influence the phenotypic expression among schwannoma tumor types. Successful completion of this study should further elucidate important pathways of vestibular schwannoma formation with good potential for future development of pharmaco-therapeutics.
描述(由申请人提供):人类前庭神经鞘瘤可引起与听力和平衡丧失、面瘫和感觉异常相关的发病率,偶尔会危及生命的脑干压迫。前庭神经鞘瘤可分为三大类-单侧自发性、2型神经纤维瘤病(NF 2)相关性和囊性前庭神经鞘瘤。虽然在临床上非常不同,神经鞘瘤肿瘤类型之间的表型变异的来源目前尚不清楚,但具有很大的临床意义。 此外,由于缺乏对基本肿瘤生物学的了解,最佳治疗方案尚不清楚。 在这三种类型的肿瘤中,NF 2相关的前庭神经鞘瘤是目前建议的主题。 NF 2相关性前庭神经鞘瘤的特征是双侧肿瘤表现。 NF 2在历史上被细分为攻击性和温和形式。 已知前庭神经鞘瘤在神经纤维瘤病2(NF 2)肿瘤抑制基因中存在突变;然而,并不是每个肿瘤都在NF 2编码区携带突变。 已经提出了NF 2调节区中突变或甲基化的可能作用。 本研究的长期目标是进一步确定和了解影响前庭神经鞘瘤表型表达的因素。本研究的主要假设是:1)转录调控在前庭神经鞘瘤肿瘤发生中起作用,2)表型表达被前庭神经鞘瘤中失调的特定生长信号通路改变。 为了支持这些假设,提出了四组实验。 在特定目标1中,他们将研究当编码区中未发现突变时,NF 2基因调控区在神经鞘瘤中的作用。具体目标2将在转基因小鼠中检查RhoB是否是雪旺细胞中NF 2蛋白的重要下游信号传导靶点。 在第三个具体目标中,他们将进行类似的转基因分析,以在Schwann细胞中过表达endoglin。 这将通过使RhoB/内皮糖蛋白转基因小鼠与条件性7Vjr 2敲除小鼠交配以确定表型是否有任何增强来实现。 在特定目标4中,他们将继续评估差异表达的基因,这可能会影响神经鞘瘤肿瘤类型的表型表达。 这项研究的成功完成将进一步阐明前庭神经鞘瘤形成的重要途径,为未来药物治疗的发展提供良好的潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
D BRADLEY WELLING其他文献
D BRADLEY WELLING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('D BRADLEY WELLING', 18)}}的其他基金
Phenotypic Determinants of Vestibular Schwannomas
前庭神经鞘瘤的表型决定因素
- 批准号:
7850077 - 财政年份:2009
- 资助金额:
$ 30.16万 - 项目类别:
Phenotypic Determinants of Vestibular Schwannomas
前庭神经鞘瘤的表型决定因素
- 批准号:
7220614 - 财政年份:2005
- 资助金额:
$ 30.16万 - 项目类别:
Phenotypic Determinants of Vestibular Schwannomas
前庭神经鞘瘤的表型决定因素
- 批准号:
6919744 - 财政年份:2005
- 资助金额:
$ 30.16万 - 项目类别:
Phenotypic Determinants of Vestibular Schwannomas
前庭神经鞘瘤的表型决定因素
- 批准号:
7064783 - 财政年份:2005
- 资助金额:
$ 30.16万 - 项目类别:
Phenotypic Determinants of Vestibular Schwannomas
前庭神经鞘瘤的表型决定因素
- 批准号:
7596919 - 财政年份:2005
- 资助金额:
$ 30.16万 - 项目类别:
相似海外基金
Structural and connectivity analysis in acoustic neuroma patients
听神经瘤患者的结构和连接分析
- 批准号:
566109-2021 - 财政年份:2021
- 资助金额:
$ 30.16万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
The molecular mechanism of hearing loss in acoustic neuroma patients.
听神经瘤患者听力损失的分子机制。
- 批准号:
17K16949 - 财政年份:2017
- 资助金额:
$ 30.16万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Safe, Rapid Access to the Internal Auditory Canal for Acoustic Neuroma
安全、快速地进入内耳道治疗听神经瘤
- 批准号:
8500735 - 财政年份:2013
- 资助金额:
$ 30.16万 - 项目类别:
Safe, Rapid Access to the Internal Auditory Canal for Acoustic Neuroma
安全、快速地进入内耳道治疗听神经瘤
- 批准号:
8610913 - 财政年份:2013
- 资助金额:
$ 30.16万 - 项目类别: